The following is a summary of “Microenhancement as a Biomarker for Cerebral Microbleed in Inflammatory Cerebral Amyloid ...
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback